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where novel therapeutic approaches are 
urgently needed, the seamless connec-
tion of therapy, diagnosis, and treatment 
response via one single system is consid-
ered to be a major step forward.[1–3] For the 
diagnostic part, various agents have been 
suggested including superparamagnetic 
iron oxide nanoparticles (SPIOs) which 
can be used as contrast agents in magnetic 
resonance imaging (MRI).[6] SPIOs feature 
a good biocompatibility and low-toxicity, 
and are superparamagnetic (for particle 
sizes equal or smaller than one single 
magnetic domain, i.e., <25  nm).[7] More-
over, when combined with drug delivery, 
theragnostics are prepared.[8–10] Whereas, 
their performance as MRI contrast agent 
is outstanding, their drug loading capacity 
is limited since the drug can be attached 
only onto the nanoparticle surface. There-
fore, various coatings have been suggested 
to enlarge the drug loading capacity of Fe3O4 nanoparticles. 
These include coating with various polymers,[11,12] mesoporous 
silica,[13,14] or graphene oxide.[15] Especially, the attempts with the 
mesoporous silica coating yielded nanoparticles with high drug 
loading.[13,14] To increase the loading capacity even more and to 
introduce some additional features such as stimuli-responsivity 
and biodegradability, we propose to combine Fe3O4 nanoparticles 
with metal–organic frameworks (MOFs).
Theragnostics represent a combination of therapy and diagnosis within one 
system. Herein, Fe3O4-ZIF-8 core–shell nanoparticles are developed and 
suggested as candidates for theragnostic applications in cancer treatment. 
A drug loaded metal–organic framework ZIF-8 (zeolitic imidazolate 
framework-8) represents the therapeutic tool, while the Fe3O4 core is included 
to enable the material visualization by magnetic resonance imaging (MRI). A 
reliable synthesis of Fe3O4-ZIF-8 core–shell nanoparticles of an average size 
below 100 nm is reported. The nanoparticles are characterized by FT-IR, TGA, 
XRPD, TEM, STEM-EDS, DLS, ICP-OES, CHN-elemental analysis, SQUID 
measurements, and MRI. Moreover, their chemical stability and in vitro 
cytotoxicity against fibroblast and selected cancer cell lines are evaluated. 
As a model drug, arsenic trioxide—a promising anticancer drug—is used. 
The drug release can be triggered by a pH change from 7.4 to 6.0 and the 
nanoparticles can be visualized by MRI in vitro, thus a potential theragnostic 
agent for cancer treatment is developed.
1. Introduction
Theragnostics represent a new highly promising field in medi-
cine.[1–4] They combine therapy and diagnosis within one system. 
Integrating diagnostic information with pharmaceuticals is highly 
attractive because it simultaneously provides a more targeted, 
efficient patient treatment and reduction of clinical costs and 
resources.[4,5] Especially in the treatment of oncological diseases, 
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MOFs represent crystalline porous coordination polymers, 
which consist of inorganic metal ions (or clusters) and organic 
ligands.[16] Due to their outstanding properties such as high 
internal surface area and chemical and design versatility,[17,18] 
MOFs have been suggested for various applications including 
gas storage and separation,[19,20] catalysis,[21–23] and also medi-
cine.[24–26] For instance, ZIF-8 (Zeolitic imidazolate frame-
work-8), composed of Zn ions and imidazolate ligands,[27] has 
been considered as a promising drug delivery system due to its 
high porosity and suitable pH-sensitive degradation.[28,29] There 
have been also reports on combining MOFs with magnetic 
nanoparticles, but this has been done mainly for catalysis[30,31] 
and extraction applications.[32,33] Up to now there have been only 
few examples of Fe3O4-MOFs for medicinal applications[26,34–38] 
and in these cases if core–shell nanoparticles have been pre-
pared,[26,34–36] they have been larger than 180 nm which is not 
optimal when an intravenous drug distribution is intended.[39]
As a model drug, we selected arsenic trioxide (ATO). ATO 
has been approved for the treatment of acute promyelocytic leu-
kemia (APL) by the U.S. Food and Drug Administration (FDA) 
in 2000[40] and by the European Medicines Agency (EMA) in 
2016.[41] These approvals promoted further research of utilizing 
ATO and other arsenic compounds in cancer therapy including 
the treatment of solid tumor entities, such as breast cancer,[42] 
cervical cancer,[43] or even brain tumors.[44] Unfortunately, 
it turned out that the treatment of solid tumors is very chal-
lenging. Due to the arsenic toxicity, the increase of dosage is 
limited, and thus the drug enrichment in the tumor is often 
insufficient. To solve this issues, using nanocarriers has been 
suggested.[40,45] So far only few materials have been tested for 
preparing delivery systems of arsenic drugs. These include 
liposomes, polymeric micelles, or mesoporous silica nanopar-
ticles.[45] Recently we also contributed to the field by developing 
MOF based nanocarriers for ATO delivery.[46–48] In this work, 
we focused on developing a theragnostic agent for delivery of 
arsenic trioxide.
2. Results and Discussion
2.1. Material Synthesis and Drug Loading
2.1.1. Fe3O4 Nanoclusters
In the reported examples of Fe3O4-MOFs,[34–36] the overall 
nanoparticle size was larger than 180  nm and the major part 
of the nanocomposite was formed by the Fe3O4 core and there 
was only a thin MOF shell. This is not optimal regarding the 
potential theragnostic applications since it seriously limits 
the drug loading capacity. Moreover, if intravenous distribution is 
intended, smaller nanoparticle sizes are preferred.[39] Therefore, 
the size of the Fe3O4 core had to be scaled down significantly.
Fe3O4 nanoclusters featuring superparamagnetic behavior 
and an overall particle size below 50  nm were synthetized by 
combining FeCl3·6H2O, sodium acetate, and trisodium citrate, 
and heating them in a mixture of diethylene glycol and eth-
ylene glycol. We discovered that the absence of water and the 
ratio of diethylene glycol and ethylene glycol were the crucial 
factors to control the cluster size. Furthermore, the addition 
of citrate and acetate to the reaction mixture resulted in highly 
hydrophilic superparamagnetic nanoparticle clusters. The ana-
lysis of the Fe3O4 nanoclusters by transmission electron micros-
copy (TEM) revealed that the size of a single nanoparticle was 
around 6.4  ±  0.8  nm, while the total nanoparticle cluster size 
was around 35.1 ± 4.5 nm (TEM, Figure 1 and Figure S2, Sup-
porting Information, calculated for 100 nanoparticles). A hydro-
dynamic diameter determined by dynamic light scattering 
(DLS) in water was 72.7 nm with a polydispersity index (PDI) of 
0.194 (Figure S5, Supporting Information).
2.1.2. Fe3O4-ZIF-8 Nanoparticles
The growth of ZIF-8 around the Fe3O4 nanoclusters was opti-
mized with a special attention paid to the solvent choice. On 
the one hand the Fe3O4 nanoclusters have to be homogene-
ously dispersed (i.e., water as solvent is preferred), on the other 
hand a moderate growth speed of the MOF shell is needed to 
ensure the actual growth onto the surface of the Fe3O4 nano-
clusters and not only alongside (i.e., methanol as solvent is 
preferred). For details, see Figure S1 (Supporting Informa-
tion). In the optimized synthesis, the Fe3O4 nanoclusters were 
dispersed in a mixture of water and methanol, and then the 
linker (2-methylimidazole) dissolved in methanol was added. 
Subsequently, the Zn(II) ions (dissolved in a mixture of water 
and methanol) were added, and the synthesis was carried out 
at room temperature. Optimal reaction conditions were deter-
mined to be 30 min of reaction time and 15 min of separation 
by applying an external magnetic field. To improve the nano-
particle biocompatibility, the surface of the nanoparticles was 
coated with polyethylene glycol—a polymer with a widespread 
use in biomedicine.[8] We used an amino-functionalized deriva-
tive of polyethylene glycol (PEG-NH2, MW 5516 Da) to enable 
coordinate interactions between the amino end-groups of the 
Figure 1. HR TEM micrographs of a) Fe3O4 nanoclusters, b,c) PEG-NH2@
Fe3O4-ZIF-8 nanoparticles, and d) a SEM micrograph of PEG-NH2@
Fe3O4-ZIF-8 nanoparticles; scale bar: (a,b) 20 nm, (c) 100 nm, (d) 1 µm.
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polymer and zinc centers of the MOF, in a way that the polymer 
is bound to the surface and a penetration into the pores of the 
framework is hindered.[49] As a result, core–shell nanoparti-
cles of overall particle sizes around 97  ±  8  nm as determined 
by TEM (Figure  1, Figures S2–S4, Supporting Information, 
calculated for 100 nanoparticles) were obtained. A hydrody-
namic diameter of these nanoparticles determined by DLS in 
water was 214.5 nm with a polydispersity index (PDI) of 0.213 
(Figure S5, Supporting Information).
2.1.3. Drug Loading
To load the core–shell nanoparticles with arsenic trioxide, we 
used sodium (meta)arsenite (NaAsO2) as the drug precursor. 
NaAsO2 is highly soluble in water, and thus a highly con-
centrated drug solution could be used. The pH value of the 
aqueous solution was adjusted to pH 7 to generate As(OH)3. 
The Fe3O4-ZIF-8 nanoparticles were kept in the solution at 
room temperature for 2 h. The surface of the drug loaded nano-
particles was coated by PEG-NH2 following the same procedure 
as for the drug free nanoparticles.
2.1.4. Material Characterization
The polymer coated samples (denoted as PEG-NH2@Fe3O4-
ZIF-8 and PEG-NH2@As@Fe3O4-ZIF-8) were characterized 
by FT-IR (Figure  2a and Figure S6, Supporting Information) 
and XRPD (Figure  2b) to verify that they comprised both 
Fe3O4 and ZIF-8. In their FT-IR spectra, besides the charac-
teristic bands of ZIF-8, bands at 590, 640, and a broadening at 
1600 cm−1 were found, which corresponded to the bands of the 
carboxylate-capped Fe3O4 nanoclusters.[50] Furthermore, bands 
at 840, 1100, 1250, and 2870 cm−1, which corresponded to C–H 
bending vibrations, O–H and C–O–H stretching vibrations of 
the PEG-NH2-coating, were detected.[49] The successful polymer 
coating was further confirmed by thermogravimetric analysis, 
which revealed that 6.1 wt% of PEG-NH2 coating were present 
(Figure S7, Supporting Information). Additionally, the visualiza-
tion of the nanoparticles by TEM confirmed that the core–shell 
type of structure was retained after the drug loading and surface 
modification (Figure 1 and Figure S2, Supporting Information).
The successful drug loading was confirmed by FT-IR spectro-
scopy. ATO is bound to the structure of ZIF-8 [Zn(C4N2H5)2] in 
a form of arsenite anions (H2AsO3−) via a post-synthetic ligand 
exchange.[48] Due to the exchange, new bands were detected at 
360, 550, 660, and 710  cm−1 (Figure  2a), which corresponded 
to the As–OH bending, the symmetric and asymmetric mode 
of stretching vibrations of As(OH)₂ and As–O.[51] To further 
validate the exchange of the imidazolate linker to the arsenite 
ligand, CHN-elemental analysis was carried out (Table S1, 
Supporting Information). In the drug free Fe3O4-ZIF-8 and 
PEG-NH2@Fe3O4-ZIF-8, the MOF sum formula was found to 
be Zn(C4N2H5)1.94 and Zn(C4N2H5)1.91, which corresponds to 
0.06 and 0.09 missing linkers per zinc cation, respectively. This 
deviation can be explained by minor defects in the framework. 
However, after the loading of arsenite (i.e., in As@Fe3O4-ZIF-8 
and PEG-NH2@As@Fe3O4-ZIF-8), the number of missing 
linkers per zinc atom increased to 0.32 and 0.33 [Zn(C4N2H5)1.68 
and Zn(C4N2H5)1.67], respectively, supporting our finding of 
the partial replacement of the linker by arsenite. The quanti-
fication of the arsenic amount by ICP-OES analysis revealed 
a ratio of Zn: As to be 1: 0.20  ±  0.02 (average value of three 
measurements) which corresponded to 53 mg of arsenic in 1 g 
of material (equivalent to 70 mg of As2O3/1 g). To visualize the 
element distribution, EDS elemental mapping was carried out 
(Figure 3 and Figure S4, Supporting Information). The overlay 
of the elements Fe and Zn in Figure  3b confirmed the core–
shell nanoparticle structure by showing the presence of Fe only 
in the core and Zn in the shell. The EDS elemental mapping 
also revealed that As was homogeneously distributed within the 
ZIF-8 shell (Figure 3g). The findings were further supported by 
the compositional map of the element O (presented in Fe3O4 
and the drug) showing a high intensity in the same area as Fe 
Figure 2. a) FT-IR spectra in the area from 2000 to 300 cm−1 and b) XRPD 
pattern of Fe3O4 (black), ZIF-8 (grey), PEG-NH2@Fe3O4-ZIF-8 (blue), and 
PEG-NH2@As@Fe3O4-ZIF-8 (red).
Part. Part. Syst. Charact. 2020, 37, 2000185
www.advancedsciencenews.com
www.particle-journal.com
2000185 (4 of 9) © 2020 The Authors. Published by Wiley-VCH GmbH
and being homogeneously distributed within the ZIF-8 shell as 
the element As.
2.2. Magnetic Properties and Magnetic Resonance Imaging
2.2.1. SQUID Measurement
The magnetic properties of the core–shell nanoparticles 
were analyzed with a superconducting quantum interference 
device (SQUID) at room temperature. The magnetization curve 
M(H) of the PEG-NH2@Fe3O4-ZIF-8 nanoparticles depending 
on the external magnetic field H is shown in Figure 4 and is 
compared to the magnetization curve of the Fe3O4 clusters. For 
both samples, starting from M = 0 at H = 0 on increasing field, 
the magnetization approaches saturation already above 5  kOe 
and returns to zero on decreasing field without any hysteresis 
effects and shows analogous behavior for inverse magnetic 
field. The saturation magnetization of the Fe3O4 nanoclusters 
was 42.6 emu g−1, i.e., about half of the bulk value,[52] while the 
magnetization of the PEG-NH2@Fe3O4-ZIF-8 core–shell nano-
particles decreased to 6.6 emu g−1. The decrease in magnetiza-
tion (expressed in emu  g−1) can be attributed to the increase 
of the overall material mass when PEG-NH2@Fe3O4-ZIF-8 
compared to carboxylate capped Fe3O4. This finding is in good 
agreement with data reported for similar materials such as 
ZIF-8/cellulose/Fe3O4 nanocomposites.[53] Since both samples 
showed no magnetization in the absence of an external mag-
netic field and no hysteresis effects, their expected superpara-
magnetic behavior could be confirmed.
2.2.2. MR Imaging and Relaxometry
We investigated the performance of the Fe3O4 nanoclusters, 
drug free PEG-NH2@Fe3O4-ZIF-8 and drug loaded PEG-NH2@
As@Fe3O4-ZIF-8 nanoparticles as MRI contrast agents. The 
nanoparticles were mixed in agar to suppress their possible 
sedimentation. The tested concentration range was from 0.1 
to 1.5 × 10−3 m (calculated for the iron content). The phantoms 
were visible as hypointense regions, both in T1 and T2 weighted 
MR images, for all tested Fe-concentrations and all the results 
are summarized in Figure 5, including the fractional signal loss 
(FSL), signal-to-noise ratio (SNR) and contrast-to-noise ratio 
(CNR). Additionally, the relaxation times T1 and T2 of all three 
materials were also evaluated and the calculated r1 and r2 and 
r2/r1 ratios are shown in Table 1. The resulting r2/r1 ratio of the 
Figure 3. EDS elemental mapping of PEG-NH2@As@Fe3O4-ZIF-8: a) Dark field STEM image, b) an overlay of Zn (green) and Fe (red) compositional 
maps and the compositional maps of c) Zn (green), d) Fe (red), e) C (light blue), f) N (dark blue), g) As (orange) and h) O (yellow); scale bar: 200 nm.
Figure 4. Magnetization loops M(H) of Fe3O4 (black symbols) and PEG-
NH2@Fe3O4-ZIF-8 (red symbols) as a function of the external magnetic 
field H measured at 300 K.
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Fe3O4 nanocluster was 48.51, and thus could be assigned as a 
“negative” contrast agent.[54] The drug free PEG-NH2@Fe3O4-
ZIF-8 and the drug-loaded PEG-NH2@As@Fe3O4-ZIF-8 nano-
particles exhibited a r2/r1 ratio of 10.67 and 12.39, respectively, 
and also provided a very good contrast in MRI (Figure 5).
2.3. Drug Release and Stability Studies
The arsenic-release kinetics were investigated in a phosphate 
buffered saline of two different pH values (pH 6.0 and pH 7.4) 
at 37 °C in order to mimic the microenvironment of tumorous 
and healthy tissues.[55] After 1, 4, 6, 24, 48, 72, and 168  h the 
amount of arsenic, iron, and zinc released into the solution 
was determined by ICP-OES (Figure 6, Figures S8 and S9, and 
Tables S3–S5, Supporting Information).
At pH 7.4 (normal tissue environment) 16.6% of arsenic was 
released after 1 h, 43.6% after 24 h and a maximum of 52.6% 
after 168 h. The burst drug release in the first few hours was not 
due to the MOF decomposition but due to the partial material 
disintegration as observed by XRPD, FT-IR, and STEM analyses 
(Figures S10–S12, Supporting Information). The results of 
XRPD analyses revealed that the intensities corresponding 
to the ZIF-8 shell decreased progressively during the release 
studies. However, the total amount of zinc released to the phos-
phate buffered saline was less than 1% (Figure S8 and Table S3, 
Supporting Information) and since no formation of zinc salts 
was detected by XRPD, the decreased signal intensity of ZIF-8 
most likely results from a progressive amorphisation of the 
framework. This was further confirmed by STEM analysis 
which revealed that after 4  h, the continuous ZIF-8 shell dis-
integrated into smaller nanoparticles located around the Fe3O4 
core with a mean particle size of 15.8  ±  3.5  nm (Figure S10, 
Supporting Information). These remained unchanged during 
the rest of the release studies and did not decompose further. 
Thus, we suggest that the significantly higher external surface 
area of those small arsenic-loaded ZIF-8 nanoparticles, which 
was consequently exposed to the phosphate buffered saline, 
was the reason for the promoted arsenic release within the first 
few hours of the release studies. Once the surface bound drug 
was released, the release did not progress due to the material 
amorphisation. Therefore, to avoid the premature release, one 
possibility would be to pre-expose the material to the phosphate 
buffered saline before the administration.
At pH 6.0 a different drug release behavior was observed. 
27.2% of arsenic was released already after 1 h, 80.2% after 24 h, 
and after 168 h all the amount of the originally loaded arsenic 
could be detected in the solution (Figure  6). This rapid and 
complete arsenic release was caused by the entire decomposi-
tion of the ZIF-8 shell at pH 6 which was accompanied by a 
progressive formation of NaZn(PO4)∙4H2O from the released 
zinc ions and phosphate anions of the buffer. The complete 
Figure 5. T1 (left side) and T2 weighted (right side) MR images of a) the Fe3O4 nanoclusters, b) the drug free PEG-NH2@Fe3O4-ZIF-8, and c) the drug-
loaded PEG-NH2@As@Fe3O4-ZIF-8 nanoparticles with different concentrations of Fe (0.1–1.5 × 10−3 m). Corresponding SNR, CNR, and FSL values for 
given phantoms are shown.
Table 1. Relaxometric properties of Fe3O4 nanoclusters, drug free PEG-
NH2@Fe3O4-ZIF-8 and drug-loaded PEG-NH2@As@Fe3O4-ZIF-8 meas-
ured at 1.5 T at 37 °C.
r1 [× 10−3 m−1 s−1] r2 [× 10−3 m−1 s−1] r2/r1
Fe3O4 3.11 150.70 48.51
PEG-NH2@Fe3O4-ZIF-8 2.37 25.25 10.67
PEG-NH2@As@Fe3O4-ZIF-8 0.76 9.46 12.39
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framework decomposition was verified by XRPD, FT-IR, and 
STEM analyses (Figures S13–S15, Supporting Information).
In addition to the ZIF-8 stability, also the stability of the 
Fe3O4 core was investigated by measuring the amount of 
iron released into the solution at pH 6 and pH 7.4 (Figure S9 
and Table S4, Supporting Information). For both pH values, 
the detected amount of iron was below 1% during the entire 
release studies indicating that the Fe3O4 core did not decom-
pose during the drug release studies.
2.4. Cytotoxicity Studies
To evaluate the cytotoxic effects of the core–shell nanoparti-
cles, both drug-loaded (PEG-NH2@As@Fe3O4-ZIF-8) and drug 
free nanocarriers (PEG-NH2@Fe3O4-ZIF-8) were analyzed. We 
selected fibroblasts as non-tumorous cells and two different 
atypical teratoid rhabdoid tumor (ATRT) cell lines, namely BT12 
and BT16, which are known to respond positively to ATO treat-
ment,[48] and incubated them with the tested materials in a con-
centration range of 0.0001–100 × 10−6 m for 24 h and 72 h. The 
amount of the administrated substances was calculated with 
respect to the constant As- or Zn-amount (Table S5, Supporting 
Information). After the incubation time, cell viability was meas-
ured performing a MTT assay.[56]
The treatment of fibroblasts with the drug free nanocarrier 
(PEG-NH2@Fe3O4-ZIF-8) showed that its cytotoxic effect was 
negligible for concentrations equal or lower than 10  ×  10−6  m 
(Figure S16, Supporting Information). For higher concentra-
tions, the cell viability decreased significantly. In the next 
step we analyzed the cell viability of fibroblasts treated with 
the drug-loaded nanoparticles (PEG-NH2@As@Fe3O4-ZIF-8) 
after 24 h and 72 h (Figure S16, Supporting Information). For 
concentrations up to 1  ×  10−6  m, the fraction vital fibroblasts 
after 72 h of incubation was similar or only slightly lower than 
that of PEG-NH2@Fe3O4-ZIF-8. However, for concentrations 
equal or higher than 10  ×  10−6  m, the cell viability decreased 
noticeably. As shown in the stability studies, the core–shell 
nanoparticles partially disintegrated at pH 7.4 within the first 
24  h and consequently some of the drug was released. We 
speculate that this drug release was most likely reflected in the 
decreased cell viability of the fibroblasts at the high adminis-
trated concentrations.
Subsequent to the studies with fibroblasts, the response of 
the ATRT cell lines BT12 and BT16 to the nanocarrier without 
and with the drug cargo was investigated. The results of PEG-
NH2@Fe3O4-ZIF-8 did not show any cytotoxic effects after 24 h 
for concentrations lower than 100 ×  10−6 m on BT12 and BT16 
cells (Figure S17, Supporting Information). The same results 
were obtained also after 72 h, even though the cell viability of 
BT16 cells was slightly unsteady for concentrations lower than 
1  ×  10−6  m (Figure 7a,b). In contrast to that, when testing the 
drug-loaded nanoparticles (PEG-NH2@As@Fe3O4-ZIF-8), 
a clear cytotoxic effect was observed already after 24  h for 
Figure 6. Arsenic-release from PEG-NH2@As@Fe3O4-ZIF-8 at pH 6 (red) 
and pH 7.4 (blue) in a phosphate buffered saline at 37 °C, determined by 
ICP-OES.
Figure 7. Cell viability of a) BT12 and b) BT16 cells after 72 h incubation 
with increasing concentrations of ATO (gray), PEG-NH2@Fe3O4-ZIF-8 
(blue), and PEG-NH2@As@Fe3O4-ZIF-8 (red). The given concentra-
tion corresponds to the concentration of As2O3 (0–100 × 10−6 m) which 
was effectively loaded or could be theoretically loaded (for details see 
Table S5†, Supporting Information). Data are presented as mean ± S.E.M 
(n ≥ 3). No cell viability was detected at 100 × 10−6 m after 72 h.
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concentrations higher than 1 × 10−6 m (Figure S17, Supporting 
Information). Herein, the cytotoxic effect was slightly more 
pronounced for BT12 cells than for BT16. This tendency was 
affirmed also after 72  h (Figure  7a,b). The comparison of the 
half maximal inhibitory concentration (IC50) values in Table 2 
shows that the specific effect of arsenic-loaded PEG-NH2@
Fe3O4-ZIF-8 on both cancer cell lines is more than eight times 
higher than the effect of the nanocarrier itself.
Lastly, we compared the cytotoxic effect of the drug loaded 
nanocarrier to the effect caused by the free drug (ATO) after 24 h 
(Figure S17, Supporting Information) and 72  h (Figure  7a,b). 
Overall, we found that their cytotoxic effects were comparable. 
For concentrations higher than 1 ×  10−6 m, the cytotoxic effect 
of ATO on BT12 was higher than the effect caused by the drug 
loaded nanoparticles (Figure 7a). However, in case of BT16 cells 
(Figure  7b), ATO caused a slightly lower cytotoxic effect than 
the drug loaded nanoparticles.
3. Conclusion
We successfully synthesized Fe3O4-ZIF-8 core–shell nanoparti-
cles with an overall particle size below 100 nm. Such materials 
are attractive not only for medicinal applications but also for 
other areas of nanoscience including catalysis or extraction. 
Here we investigated their theragnostic potential: on the one 
hand as nanocarriers of arsenic trioxide (which was enabled by 
the porous MOF shell), on the other hand as contrast agents 
in MRI (which was enabled by the superparamagnetic Fe3O4 
core). A SQUID measurement confirmed that the core–shell 
nanoparticles were superparamagnetic. Further, the results 
obtained by MR imaging affirmed that indeed the Fe3O4-ZIF-8 
nanocarrier could be visualized by MRI. To demonstrate the 
drug delivery function, the MOF shell was loaded with arsenic 
trioxide. The drug was introduced to the framework via a post-
synthetic ligand exchange with loading of 53 mg of arsenic per 
1  g (equivalent to 70  mg of As2O3/1  g). The drug release was 
investigated in a phosphate buffered saline at two different pH 
values—7.4 and 6.0. At pH 6, the porous ZIF-8 shell decom-
posed rapidly and entirely while inducing a complete drug 
release. Whereas at pH 7.4, approximately only half of the loaded 
drug was released after 168 h. In addition, the results of the in 
vitro cytotoxicity studies showed that the drug free nanocarrier 
did not cause critical harm neither to the fibroblasts nor to the 
selected cancer cell lines at moderate concentrations. In case of 
the drug-loaded nanoparticles, a substantial cytotoxic effect was 
observed on the cancer cell lines, while on fibroblast, a cytotoxic 
effect was detected only at higher concentrations. Thus, there 
was a considerable difference in the drug release and cytotox-
icity in the different cell lines, and we could indeed observe a 
cell specific drug release, which is a highly desirable feature 
in cancer treatment. Inspired by the results, we encourage a 
further development and study of Fe3O4-MOF core–shell nano-
particles, and Fe3O4-ZIF-8 in particular, for theragnostic appli-
cations. For instance, we are currently working on combining 
the Fe3O4-ZIF-8 nanoparticles with targeting ligands and inves-
tigating their potential in cancer therapy.
4. Experimental Section
Materials and Methods: All reagents were of analytical grade and used 
as received from commercial suppliers: iron(III) chloride hexahydrate, 
anhydrous sodium acetate, trisodium citrate dihydrate, ethylene glycol, 
diethylene glycol, zinc nitrate hexahydrate, sodium (meta)arsenite, 
2-methylimidazole and arsenic trioxide from Sigma-Aldrich, and alpha-
monomethoxy-omega-amino poly(ethylene glycol) from Iris Biotech 
GmbH. Fourier transform infrared (FT-IR) spectra were recorded in the 
range of 400–4000  cm−1 on a Bruker Equinox 55 FT-IR spectrometer 
equipped with an ATR unit. Thermogravimetric analysis was measured 
on a TA Instruments Q500 device in a temperature range of 25–700 °C 
under a nitrogen atmosphere at a heating grade of 10  °C  min−1. X-ray 
powder diffraction data were collected in the 4–70° 2θ range using a 
Bruker D8 Advance diffractometer with Cu-Kα radiation (λ  =  1.54184) 
with a 1D LynxEye detector. The samples were ground and filled into 
a Hilgenberg glass capillary (outer diameter 0.3  mm, wall thickness 
0.01  mm). TEM micrographs and EDS elemental mappings were 
recorded with a JEM NEOARM microscope (JEOL) with a cold FEG 
electron source operated at 200 kV. SEM and STEM micrographs were 
recorded with a Crossbeam 550 Gemini II (ZEISS) with a FE-Gun 
operated at 30 kV. Samples were prepared by depositing a drop of the 
crystalline products dispersed in ethanol onto carbon-coated copper 
grids (200 mesh) and dried in air. The size of the nanoparticles was 
determined from calibrated TEM images using ImageJ software.[57] 
One hundred particles were analyzed to determine the average size. 
Dynamic light scattering (DLS) measurements were carried out using 
a Brookhaven 90Plus Nanoparticle Size Analyzer. Nanoparticles were 
dispersed in water prior the measurement. The elemental composition 
of solid and liquid samples was determined by ICP-OES with the 
Vista MPX of VARIAN with arsenic, iron, and zinc standard solution 
of 10 and 20  ppm. The samples were decomposed or diluted in an 
aqueous solution of HNO3 prior to the measurement. CHN-elemental 
analysis was measured with a Vario EL III (Elementar-Analysensysteme 
GmbH). Cells were cultivated in a Heracell 150i CO2 incubator (Thermo 
Scientific). MTT assay was analyzed using a Multiskan Ascent Microplate 
Reader (Thermo Electron Corporation). Magnetization loops M(H) as a 
function of the external magnetic field H were recorded with a Quantum 
Design MPMS 5 SQUID magnetometer at constant temperature in a 
field range between −50 and +50 kOe.
Synthesis of Fe3O4 Nanoclusters: FeCl3·6H2O (3.468  g), anhydrous 
sodium acetate (7.68  g) and trisodium citrate dihydrate (2.08  g) were 
dissolved in a mixture in 40  mL of ethylene glycol and 120  mL of 
diethylene glycol. Then the solution was stirred for 1  h at 120  °C (N2-
atm), transferred to a Teflon-lined stainless-steel autoclave (200  mL 
capacity) and heated at 200  °C for 10  h. The product was separated 
by using an external magnetic field and washed well with ethanol and 
deionized water. Finally, the nanoparticle clusters were dispersed in 
100 mL of distilled water to store them.
Synthesis of Fe3O4-ZIF-8 Nanoparticles: To 17  mg of the Fe3O4 
nanoclusters dispersed in 1.6  mL of distilled water and 5  mL of 
methanol, 2-methylimidazole (850  mg, 0.01  mol) dissolved in 25  mL 
Table 2. Half-maximal inhibitory concentrations (IC50) values of selected 
materials after 72  h (the given IC50 values correspond to the concen-
tration of As2O3 which was effectively loaded or could be theoretically 
loaded).
IC50 value [× 10−6 m] after 72 h ATRT cell line. Ref.
BT12 BT16
PEG-NH2@Fe3O4-ZIF-8 28.0 20.5 This work
PEG-NH2@As@Fe3O4-ZIF-8 3.3 2.0 This work
ATO 1.4 6.1 [44]
ZIF-8 12.5 12.8 [46]
PEG-NH2@As@ZIF-8 2.4 2.1 [46]
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of methanol was added. The mixture was ultrasonicated for 15  min, 
mixed with a solution of Zn(NO3)2·6H2O (89 mg, 0.5 mmol) in 10 µL of 
distilled water and 10 mL of methanol and kept at room temperature for 
30 min. After further 15 min of applying an external magnetic field, the 
material was washed with methanol (3 × 20 mL).
Drug Loading: An aqueous solution of sodium (meta)arsenite solution 
(7.7  ×  10−3  m) of pH 7 was prepared by dissolving sodium (meta)
arsenite NaAsO2 (1 g, 7.7 mmol) in 1 L of distilled water and subsequent 
adjustment of the pH with 1 m hydrochloric acid. 45 mg of the prepared 
Fe3O4-ZIF-8 nanoparticles were dispersed in 16 mL of distilled water and 
8  mL of the freshly prepared 7.7  ×  10−3  m aqueous arsenite solution 
and kept at room temperature for 2  h. The material was isolated by 
applying an external magnetic field for 30  min, washed with deionized 
water (3 × 20 mL) and dried under ambient pressure at 75 °C.
Coating Nanoparticles with Amino-Functionalized Polyethylene 
Glycol: 45  mg of the drug free or loaded Fe3O4-ZIF-8 nanoparticles 
were dispersed in 5  mL of a 1.6  ×  10−3  m aqueous solution of alpha-
monomethoxy-omega-amino poly(ethylene glycol) (PEG-NH2) and 
kept at room temperature. After 2 h the respective sample was placed 
into an external magnetic field for 30  min, washed with deionized 
water (3  ×  20  mL) and dried under ambient pressure at 75  °C. The 
drug free (PEG-NH2@Fe3O4-ZIF-8) and drug loaded (PEG-NH2@As@
Fe3O4-ZIF-8) materials were characterized by XRPD, FT-IR, TGA, TEM, 
ICP-OES, CHN-elemental analysis, EDS elemental mapping, SQUID, 
and in vitro MRI.
MR Imaging and Relaxometry: T1 and T2 weighted MR images of the 
phantoms containing the nanoparticles were acquired on a 4.7 T Bruker 
Biospec scanner using a resonator coil (Bruker, Biospin, Germany). A 
standard 2D rapid acquisition with relaxation enhancement (RARE) 
multi-spin echo MR sequence with spatial resolution 141  ×  141  µm2, 
and slice thickness of 1  mm was used. Following parameters of MR 
sequence were used: T1 weighted MR images acquisition: TR = 300 ms, 
TE  =  1.6  ms, turbo factor  =  1; for T2 MR weighted images acquisition: 
TR = 3000 ms, TE = 50 ms, turbo factor = 2. MR image processing and 
quantification were performed using ImageJ software.[57] The signal-to-
noise ratio (SNR) was calculated using SNR = 0.655 S/σ equation, where 
S is signal intensity in the region of interest, σ is the standard deviation 
of background noise and constant 0.655 reflects the Rician distribution 
of background noise in a magnitude MR image. The contrast-to-noise 
ratio (CNR) was calculated as the difference in SNR between phantom 
and water. The fractional signal loss (FSL) was calculated as percentage 
signal drop in phantoms related to the water signal intensity.
The relaxivity of nanoparticles was measured on a 1.5  T Minispec 
60  MHz relaxometer (Bruker Biospin, Germany) at stabilized 
temperature of 37  °C during the whole experiment. T1 relaxation times 
were measured with the inversion recovery sequence (repetition 
time (TR)  =  0.01–10 000  ms, recycle delay  =  2  s, scans  =  4, echo time 
(TE) = 0.05 ms, 20 points for fitting). T2 relaxation times were measured 
with Carr–Purcell–Meiboom–Gill sequence (TR  =  10 000  ms, recycle 
delay  =  2  s, scans  =  8, TE  =  0.05  ms, 20 000 points for fitting). The 
relaxivities r1,2 were calculated through the least-squares curve fitting 
of R1, R2 relaxation rates [s−1] versus iron concentration [×10−3 m]. 
To prevent sedimentation of nanoparticles during the measurement 
(t = 5 min), samples were fixed in 1% agar solution.
Drug Release: 10  mg of PEG-NH2@As@Fe3O4-ZIF-8 were dispersed 
in 10 mL of 0.01 m phosphate buffered saline of pH 7.4 or 6.0. At a certain 
period of time (after 1, 4, 6, 24, 48, 72, or 168 h), 1 mL of the solution 
was removed for analysis and replaced by 1  mL of a fresh phosphate 
buffer solution. The amount of arsenic, iron, and zinc in the taken 1 mL 
of the sample was determined by ICP-OES analysis. The release studies 
were done in triplicates and the data are presented as mean ± standard 
deviation. Moreover, the remained nanoparticles after 4, 24, and 168  h 
were analyzed by XRPD, IR, STEM, and ICP-OES analyses.
Cell Culture: ATRT cell lines were cultured as suspension cells in NSC 
growth medium (DMEM/F12/Ham medium supplemented with B27 
supplement (2%), N2 supplement (1%), penicillin and streptomycin 
(1%), recombinant EGF (20  ng  mL−1) and recombinant FGF 
(20 ng mL−1). BT12 cells were received from Dr. Marc Remke (University 
of Düsseldorf, Germany) and BT16 cells from Dr. Martin Hasselblatt 
(University of Münster, Germany). Fibroblasts were provided by Niki 
Loges (University of Münster, Germany). All cells were cultured in 5% 
CO2 at 37 °C. All cell lines were authenticated by STR-PCR profiling and 
regularly tested for mycoplasma.
Cytotoxicity Studies: Cells were seeded in a 96-well plate at a density 
of 4000 (fibroblasts), 4000 (BT16), or 8000 (BT12) cells per well. After 
24  h, cells were treated with increasing concentrations (concentration 
range 0–100  ×  10−6  m, calculated with respect to the constant As- or 
Zn-amount) of PEG-NH2@Fe3O4-ZIF-8, PEG-NH2@As@Fe3O4-ZIF-8, or 
ATO and incubated for 24 or 72 h. On the day of measurement, 10 µL 
of MTT reagent was added. Viable cells were converted tetrazolium 
dye MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
into an insoluble, purple-colored formazan dye. After 3  h incubation 
time, formazan crystals were resuspended with 100 µL of isopropanol–
HCl (0.04  N). MTT assay[52] was performed using a Multiskan Ascent 
Microplate Reader (Thermo Electron Corporation). The absorbance 
was measured at a wavelength of 570  nm and a reference wavelength 
of 630  nm. Data were analyzed using GraphPad Prism software 
version 7.00.
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